Filana Therapeutics, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | |
| – | +0.4% | -15.4% | -0.9% | -39.9% | +180.2% | -33.8% | +23.5% | – | |
| – | +2.4% | -9.0% | -12.3% | -3.9% | +22.1% | -24.3% | +0.0% | – | |
| – | -1,149.5% | – | +420.7% | -99.8% | -5,666.0% | – | – | – | |
| – | +235.3% | -100.0% | – | – | +526.3% | -100.0% | – | – | |
| – | +235.3% | – | – | – | +526.3% | – | – | – | |
| – | – | -90.2% | -100.0% | – | – | -84.5% | -68.6% | – | |
| – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.